SCHEMBL3598706

SCHEMBL3598706

C[C@](N)(Cc1ccccc1)c1nnc(-c2cc(C(=O)O)cc(-c3ccccc3C#N)c2)o1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.52
BACE2 Q9Y5Z0 1/20 0.45
CTSA P10619 3/20 0.40
MYC P01106 1/20 0.37
WDR5 P61964 1/20 0.37
GSK3A P49840 2/20 0.37
GSK3B P49841 2/20 0.37
UCHL5 Q9Y5K5 2/20 0.36
EGLN1 Q9GZT9 2/20 0.35
APLNR P35414 1/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
XDH P47989 1/20 0.34
ATR Q13535 1/20 0.34
SLC22A12 Q96S37 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3595507 1.00 BACE1 (0.52) BACE1BACE2CTSAMYCWDR5
SCHEMBL3598702 1.00 BACE1 (0.52) BACE1BACE2CTSAMYCWDR5
SCHEMBL16168404 0.91 BACE1 (0.49) BACE1BACE2CTSAMYCWDR5
SCHEMBL8285933 0.91 BACE1 (0.49) BACE1BACE2CTSAMYCWDR5
SCHEMBL3601751 0.90 BACE1 (0.49) BACE1BACE2CTSAMYCWDR5
SCHEMBL12993778 0.90 BACE1 (0.51) BACE1BACE2CTSAMYCWDR5
SCHEMBL3601755 0.90 BACE1 (0.49) BACE1BACE2CTSAMYCWDR5
SCHEMBL13041744 0.89 BACE1 (0.54) BACE1BACE2CTSAMYCWDR5
SCHEMBL12993809 0.89 BACE1 (0.51) BACE1BACE2CTSARAB9AALDH1A1
SCHEMBL12993842 0.88 BACE1 (0.52) BACE1BACE2CTSAMYCWDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740559-B1 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2014-10-15 EP disclosed
US-7847100-B2 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease Merck, Sharp & Dohme, Inc. (US) 2010-12-07 US disclosed
EP-1740559-A4 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO INC (US) 2007-12-12 EP disclosed
US-20070244119-A1 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK SHARP & DOHME LLC 2007-10-18 US disclosed
EP-1740559-A1 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck & Co., Inc. (US) 2007-01-10 EP disclosed
WO-2005103020-A1 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244119-A1 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease BACE1, BACE2, PSEN1 BACE1 1/4885BACE2 2/4885CTSA 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.